Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.idcr.2020.e00864 http://scihub22266oqcxt.onion/10.1016/j.idcr.2020.e00864 32566483!7298522!32566483     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       IDCases 2020 ; 21 (ä): e00864 Nephropedia Template TP {{tp|p=32566483|t=2020. Doxycycline as a potential partner of COVID-19 therapies |pdf=|usr=}}{{32566483}} gab.com Text Doxycycline as a potential partner of COVID-19 therapies JO: IDCases http://www.kidney.de/pget.php?&tw=1&pmid=32566483 #FOAvip Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage. Twit Text FOAVip Doxycycline as a potential partner of COVID-19 therapies ????IDCases http://www.kidney.de/pget.php?&tw=1&pmid=32566483 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32566483 #FOAvip English Wikipedia <ref>{{Cite pmid|32566483}}</ref> Doxycycline as a potential partner of COVID-19 therapies #MMPMID32566483 Malek AE; Granwehr BP; Kontoyiannis DP IDCases 2020[]; 21 (ä): e00864 PMID32566483show ga Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage. äDoxycycline as a potential partner of COVID-19 therapies (epmc).pdf DeepDyve Pubget Overpricing